Takara Holdings: long-term performance & turning pointsSales (revenue) and profit-margin ratio
Sales (¥ bn)Net margin (%)
1925Never a single-product brewery
Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports
1842The Shikata family begins brewing in Fushimi
1916Omiya Kurakichi joins; new-style shochu becomes the mainstay
1925Incorporated as Takara Shuzo with a deliberately broad charter
1949Listed in Tokyo, Osaka and Nagoya
1954First in the Japanese liquor industry — fourteen plants
The line runs back to the Shikata family, brewing in Fushimi — Kyoto’s sake district — since 1842. Shikata Unosuke incorporated Shikata Gomei in 1905 on three products, none of them sake: mirin, shirozake and shochu. The Takara mark had been registered on mirin in 1897. In 1916 the family brought in Omiya Kurakichi from Uwajima, who made continuous-still “new-style” shochu the mainstay and expanded the Fushimi works; Takara originated bottled shochu, and nationally the name simply meant shochu. When the firm was reorganized as Takara Shuzo in September 1925 with ¥550,000 of capital, its articles listed “liquor, alcohol, soft drinks, pharmaceutical goods, seasonings” — a deliberately wide charter, in the middle of the country’s most famous sake town.
What followed was growth by absorption: breweries in Chiba (1926), Tokyo (1929), Hiroshima (1929) and Yamaguchi (1939), and in 1933 a new company for the Shochikubai sake brand across four plants. When new-style shochu drew a crowd of entrants into a price war, Takara organized the national federation that imposed output limits on the whole trade. The war then converted the firm into an alcohol producer for the state, with ventures in Manchuria (1940) and Hong Kong (1943) that were both confiscated at the surrender, and a role in founding the aviation-fuel company that became Kyowa Hakko.
The postwar decade was acquisition again, now with the state selling. Takara bought a plant from Daikoku Budoshu in 1947, absorbed Nihon Seisei that September, listed in Tokyo, Osaka and Nagoya in May 1949, took two government alcohol monopoly plants at auction in 1952, and added three more works by merger the same year. By the year to March 1954 it ran fourteen plants and shipped 494,000 koku worth ¥12.78bn — 30% of Japan’s shochu, 70% of its mirin, 20% of the monopoly alcohol — and stood first in the Japanese liquor industry. In September 1955 it obtained a beer licence.
1957The beer that failed, the laboratory that did not
Revenue (¥ bn, bars) · net margin (%, line)
Source: securities reports
FY1966 · unconsolidated
Revenue$61M
Net income$197K
Net margin0.3%
→
FY1976 · unconsolidated
Revenue$151M
Net income$3M
Net margin2%
1957Beer launched at the Kizaki plant
1962Kansai entry fails; five years without a dividend
1967Full exit from beer — plants sold to Kirin and Sapporo
1970Central research laboratory opened in Otsu, five staff
Takara entered beer in April 1957 with a plant at Kizaki, and it was Omiya Kurakichi’s personal wager — the licence granted it a larger first-phase allocation than any of the three incumbent brewers. A Sapporo plant followed in 1959 and a Kyoto plant in 1962 to attack the Kansai market. The problem was not the beer but the channel: wholesalers of the day carried one brand exclusively, and a latecomer could not buy its way in. Building the second plant made the failure worse rather than better. Takara Beer went five straight years without a dividend from 1962, and by the year to March 1966 ordinary profit had fallen to ¥63m.
When Omiya Takashi became president in 1966, the first thing he did was shut down his adoptive father’s life’s work — “if we go on like this the company will collapse.” He toured the customers himself to explain, used the banks as intermediaries, and sold the Kyoto plant to Kirin in July 1967 and the Kizaki plant to Sapporo in April 1968: a complete exit ten years after entry, followed by more than a thousand job cuts over thirteen years. Ordinary profit recovered from ¥63m to ¥505m in a single year.
And in the middle of that retrenchment, in September 1970, Takara opened a central research laboratory in Otsu with five people under Dr Tanabe Osamu — and an annual running cost of about ¥100m, against a company that had earned ¥63m of ordinary profit in 1966. Colleagues objected that this was no time to fund something with no near-term return. Omiya kept it on the argument that a company fed for generations by fermentation owed something back, and cut everything except researchers. The lab’s foundation was exactly the microbiology Takara had accumulated making shochu and alcohol, and it eventually produced Japan’s first restriction enzymes — the beginning of everything the company would become.
1988Exclusive Japanese rights to PCR amplification reagents
2000Dragon Genomics announced — a ¥6bn analysis centre
In the year to March 1975 sake was still Takara’s largest product at 44% of parent revenue against shochu’s 18%. Then in 1977 came Takara Shochu “Jun,” and shochu stopped being a middle-aged man’s drink: mixed with soda as a sour, or as a cocktail base, it reached young drinkers and women, and a nationwide boom followed. Japan’s first canned chu-hi arrived in 1984 and sold ¥13.6bn in its first full year. By the year to March 1985 shochu was ¥56.4bn — 43% of parent revenue, ahead of sake’s 22% — on ¥130.1bn of sales and ¥14.3bn of ordinary profit, and Takara was the industry’s largest company.
That was exactly when president Kukita Minoru decided to spend. His reasoning was that diversifying after the core business weakens is dangerous, so the time to plant the next pillar is while shochu is still healthy — and by autumn 1985 shochu volumes were already falling year on year. Takara had bought a California sake brewery in 1982; in February 1986 it set up a Scottish subsidiary and bought the assets of Tomatin, one of Britain’s largest malt distillers, then in liquidation, for £2.5m — with management saying openly that breaking even in five years would be fine. Age International, the Kentucky bourbon house, followed in 1991–92, and Chinese ventures in 1993 and 1995.
Meanwhile the laboratory finally started to pay. Takara won exclusive Japanese distribution of Perkin-Elmer’s PCR gene-amplification system in 1988, commercialized contract genome analysis in 1990, and by 1999 that business was running at roughly ¥10bn of sales and ¥3bn of operating profit. In April 2000 the company announced Dragon Genomics, a ¥6bn high-speed genome analysis centre in Mie, explicitly aimed at contesting Celera’s lead before American gene patents closed the field — with about 80% of capacity sold as contract analysis so that the venture earned while it competed. President Omiya Hisashi saw the gene-therapy adjuvant RetroNectin as the future revenue source, and moved to spin the genome business out for speed.
2002Split into Takara Shuzo, Takara Bio and a holding company
2004Takara Bio listed separately
2010FOODEX in France — the first Japanese-food distributor
2017Takara Shuzo International established
2022PCR demand lifts group revenue to a record ¥300.9bn
2026Takara Bio taken fully private and delisted
In April 2002 Takara Shuzo split itself in three. Liquor, food and alcohol went to a new Takara Shuzo; the biotech business, including the 1970 laboratory, went to a new Takara Bio; and the old company became a pure holding company, Takara Holdings. The logic was that a mature, cash-generative liquor business and a research business that buys growth by spending first cannot be measured on the same ruler inside one legal entity. Takara Bio listed separately on Mothers in December 2004 and bought Clontech Laboratories in California in 2005, then Rubicon Genomics and WaferGen in 2017. Even so, in the year to March 2005 liquor and food were still 91% of consolidated revenue against biotech’s 7%.
What actually replaced shochu as the growth engine was neither. Domestic sake, shochu and mirin were shrinking, while Japanese food was spreading abroad — and Takara chose to buy the unglamorous middle of that trade rather than push its own brands. It began with 80% of FOODEX in France in 2010, then Tazaki Foods in Britain (2013), Comindport in Spain (2014), Mutual Trading in the United States (2016) and Nippon Food in Australia (2017). In July 2017 the overseas business was hived off into Takara Shuzo International as a direct subsidiary of the holding company, and president Kimura Mutsumi made clear these deals were sought out rather than offered. Tokyo Kyodo Boeki followed in 2020, and Tsukiji Ota, Agrica and Germany’s Kagerer in 2024.
By the year to March 2025, Takara Shuzo International was ¥185.4bn — 53% of group revenue — against ¥118.8bn for domestic liquor and ¥45.0bn for biotech, with roughly 60% of the group’s sales earned overseas. The other half of the 2002 design, meanwhile, unwound. COVID took Takara Bio’s segment revenue from ¥34.6bn to ¥67.7bn and its profit from ¥6.3bn to ¥28.9bn in two years, lifting the group to a then-record ¥300.9bn of revenue; then the demand vanished, US research funding was cut, Chinese competitors arrived, and by the year to March 2026 the segment posted a ¥4.7bn operating loss. In May 2025 management said the parent-subsidiary listing caused no harm. Nine months later, on 13 February 2026, it announced a ¥54.1bn tender offer at ¥1,150 a share, and on 12 June 2026 Takara Bio was delisted — twenty-four years after it was created to stand on its own.
The weight of this decision does not fit inside the phrase “tidying up an unprofitable business.” What was being withdrawn from was the venture that Omiya Kurakichi — former chairman, and his adoptive father — had begun with the company’s fortunes staked on it. That Omiya Takashi, only just succeeded to the presidency, folded that ambition as the first act of his tenure is where the tension of this decision is concentrated. Fearing that taking time over a decision loses the opportunity, he pushed it through over objections all at once — a way of working he later looked back on with the word “one-man.”
That said, one can only assert that the withdrawal saved the company because one knows what came after. While letting go of beer and heading into contraction, the firm cut headcount on the one hand and set aside money for a laboratory that would not pay in the near term on the other. It was the judgment of that rebuilding period, defence and offence advancing together, that prepared both the revival of shochu and the seed of biotech. The quality of management shows less in the failure itself than in how the failure is folded up and what is planted next — Takara Shuzo’s exit from beer can be read as one instance of that.
The core of this decision is that in the hardest period, the investment chosen was the one furthest from recovery. Committing running costs greater than ordinary profit to a laboratory is difficult to justify on the finances of the time. That Omiya Takashi could nonetheless override the objections was, it seems, because a conviction about the fermentation technology gained in brewing coincided with a fear that contraction alone would leave the company thin. The rhythm of management that decided withdrawal and investment in the same period tells you the character of this judgment.
But to praise this only as foresight, on the grounds that the investment reached as far as the peak of PCR demand half a century later, simplifies the story too much. It took nearly twenty years for the laboratory to produce results, and in between lay patient basic research and the accumulated judgments of the managers who followed. When a single investment bears fruit as a business after a long passage of time, it requires as much decision to continue as the first decision took. The history of the central laboratory says that quietly.
Planting the next thing while the core business is strong sounds, put into words, like plain good sense. In practice it requires the resolve to allocate money and people to an overseas business of unreadable outcome while the earner is doing well. That Takara Shuzo could carry it out was, it seems, because the memory of having damaged the core business with the beer withdrawal remained in management. This company knew from experience that the shochu boom would end someday. That it moved at the peak is precisely where the force of this judgment lies.
That said, most of the seeds sown at this point did not flower. Neither whisky nor bourbon became a pillar of the business, and this diversification was not what rescued the company from stagnation in the 1990s. Even so, the experience of buying and running things overseas stayed with the company. When, more than twenty years later, that experience bore fruit in the different form of Japanese-food distribution, the diversification of the 1980s can in hindsight be read as a long piece of foreshadowing. Whether an advance investment succeeds is often decided somewhere other than where the investor imagined.
Putting two different currents into two different companies
At the core of this split is the judgment to re-house two currents of different character — liquor and biotech — in separate companies. Keep the stable earnings of mature liquor and a biotech business that spends first to buy growth inside one entity, measured on the same ruler, and both readings blur. The idea of giving each business its own management and its own dialogue with the capital markets can be read as the choice of a company that had spent half a century since the central laboratory of 1970 raising a second pillar, and now wanted that pillar to stand on its own. The moment when pandemic PCR demand lifted the whole group’s results is one instance of the arrangement working as designed.
That said, the judgment to put the two into separate companies also created a problem that has outlasted twenty years. Takara Bio, sent out as a listed subsidiary, found the terms of parent-subsidiary listing re-examined as the special demand receded, and in 2026 was taken back into the fold through a tender offer. Reorganizing a business by carving it out and making it independent is a source of funding power in the growing years, and in the stagnant years it summons a different question: how to deal with the capital tied up and the listed subsidiary held. What Takara Holdings faces now is how to fold up, in its next form, the two-business arrangement it chose for itself a quarter of a century ago.
From a company that makes liquor to a company that carries Japanese food
At the core of this shift is that a company which made and sold liquor moved its mainstay to distributing Japanese food itself to the world. While domestic sake, shochu and mirin struggled in a mature market, abroad the spread of Japanese food was lifting the wholesalers who work behind the scenes. Rather than growing its own brands overseas, Takara Holdings bought up the distribution networks that deliver Japanese ingredients locally, and with the 2017 spin-off bundled them into an independent holding company. It can be read as the process by which a company that makes things strengthened the character of a company that carries and delivers them.
That said, scale as a distribution business comes with a different placement of risk than brewing. How to make wholesalers bought in various countries mesh as a single group, and how to absorb the swings of restaurant markets, tariffs and food regulation, remain unanswered questions at the time of writing. That overseas now earns the majority of revenue also means a structure in which the company’s fortunes are governed by overseas restaurant demand. Whether the image chosen by an old house of Fushimi — “a company that sells Japanese food” — becomes a stable pillar over the next hundred years depends on how skilfully the integration is done.
A parent-subsidiary listing that came full circle in 24 years
At the core of this acquisition is a return to origins: a business once made independent for the sake of growth, gathered back into the parent’s hands after its results sank. The 2002 split and the 2004 listing were designed to open an independent funding route for biotech as a growth business. In the growing years that design drew outside capital, and during the pandemic’s PCR demand it lifted the whole company’s numbers. But once the special demand receded and the external environment changed abruptly, the same listed-subsidiary structure flipped to the side that constrains nimble decision-making and capital efficiency. In the swing from denying any harm from the parent-subsidiary listing one year to moving to dissolve it in less than twelve months, one glimpses both the speed of change in the business environment and the difficulty that the standing of each business changes places over time.
That said, taking the company private is only the entrance to rebuilding Takara Bio. There is no guarantee that the external environment — US research budgets, competition from Chinese firms — improves merely because it has been returned to the parent’s hands. Whether the choice to commit ¥54.1bn of borrowed money, directing part of the capital it holds into absorbing a listed subsidiary, connects to a recovery in earning power and an improvement in capital efficiency is still not visible at the time of writing. What a company that has built scale through M&A now faces is not buying a new earner, but how to make fresh use of the two-business arrangement it chose for itself a quarter of a century ago.
Each heading links to the full Japanese analysis — background, decision and outcome, with sources.
This is a condensed English edition. The full, source-by-source history — with the detailed narrative, financial tables, shareholders and executives — is maintained in Japanese: 日本語版（詳細）— Takara Holdings full history in Japanese →
Takara Holdings Inc. — 有価証券報告書 (annual securities reports).
Corporate Histories: A Hundred Years of Meiji — 『企業の歴史：明治百年』 (Keizai Shunjusha, 1968).
Nikkei Business — 日経ビジネス (Nikkei BP): 2 Nov 1981 (case study on Takara Shuzo); 31 Mar 1986 (the whisky and soft-drink move); 2 Mar 1992 (Omiya Takashi, “be a one-man in the hard times”); 14 Feb 1994 (Omiya Hisashi on succeeding); 17 Apr 2000 (Dragon Genomics against Celera).
Weekly Toyo Keizai — 週刊東洋経済: 26 Feb 2000; 5 Aug 2000 (“Bet on biotech”); 12 Aug 2000 (the genome business); 3 Nov 2018 (the three companies behind Japanese food abroad).
Takara Holdings Inc. — earnings briefing materials (決算説明会), May 2024 and May 2025.
Takara Holdings Inc. — tender offer announcement for Takara Bio Inc., 13 February 2026.
This page is provided for general information only and is not investment advice, nor a recommendation to buy or sell any security.
Figures are compiled independently and include our own estimates, approximations and machine-processed data; we make no warranty as to their accuracy or completeness.
Sources are primarily each company’s securities reports and other public filings, but errors and omissions may remain.
Any use of this information is at the reader’s own risk. Past performance does not indicate future results.
Company names, logos and other marks belong to their respective owners.
Data API
Takara Holdings’s history, financials, executives and
shareholders are published as static JSON — no key, plain GET.